CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Raising the Evidentiary Bar for Guideline Recommendations for TAVR: JACC Review Topic of the Week 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Comprehensive intravascular ultrasound assessment of stent area and its impact on restenosis and adverse cardiac events in 403 patients with unprotected left main disease The impact of intravascular ultrasound guidance during drug eluting stent implantation on angiographic outcomes Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine - The ROPA-DOP Trial Histopathologic validation of the intravascular ultrasound diagnosis of calcified coronary artery nodules Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review Revascularization in Patients With Left Main Coronary Artery Disease and Left Ventricular Dysfunction

Guideline2014 Jul 1;63(25 Pt B):2889-934.

JOURNAL:J Am Coll Cardiol. Article Link

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone NJ, Robinson JG, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Keywords: ACC/AHA Practice Guideline; biomarkers, pharmacological; cardiovascular disease; cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction behavior; secondary prevention

Full Text PDF